Breast Cancer: SWOG S0221 (Hematology Oncology Associates)

SWOG S0221: Phase III Trial of Continuous Schedule AC +G vs Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Op Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer.

Objective

The main purpose of this study is to compare the effects (good and bad) of two different treatments (or “regimens”) for breast cancer that is considered high risk. These two treatments include essentially the same drugs given in different ways and on different schedules. All of the treatments use standard, commercially available medicines that are known to be effective for treating breast cancer.

Principal Investigator(s)
Shobha Chitneni

Clinical Trial Categories

  • Cancer
  • Breast Cancer
Sponsor(s)
SWOG
Contact
Katy D'Aprile, RN, BSN at 563-355-7733

Location

  • Hematology Oncology Associates of the Quad Cities
    1351 East Kimberly Road
    Suite 100
    Bettendorf, IA 52722

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email